(Figure 1) The observed ~2% HbA1c reduction in both arms is clinically meaningful and aligns with outcomes seen in global semaglutide trials
The BMI considerations for GLP-1 therapy extend beyond initial qualification and into decisions about treatment duration
Developing a Long-Term Management Plan For most people, the sensation of feeling cold is most intense during the initial phases of weight loss or when increasing a dose
According to a 2025 survey by KFF, less than 1 in 4 employers currently cover GLP-1s when used primarily for weight management
In this article, we compare several leading platforms, including Eden, Ro, and Henry Meds, highlighting key areas like pricing transparency, provider access, and ongoing tools that may support patients during their treatment journey